Publications
Cost-effectiveness of nivolumab and ipilimumab versus pembrolizumab and axitinib in advanced renal cell carcinoma with intermediate or poor prognostic risk: a Brazilian private healthcare system perspectivePublications
Explore the expertise, insights, and perspectives from OPEN Health that help transform complexity into clarity across today’s healthcare landscape.